11 Books You Can’t Miss in 2019

Changing the site of care to less expensive locations. and putting biosimilars are favored strategies, according to a survey conducted by the National Alliance of Healthcare Purchaser Coalitions

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.

Here’s what you missed this week on Managed Healthcare Executive.

In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.

Larimar has undertaken an ongoing open-label extension study of nomlabofusp with the first enrolled patient being dosed in March 2024.

After experiencing setbacks, PTC reported positive results for vatiquinone, its selective inhibitor of 15-Lipoxygenase (15-LO) enzyme, regulator of the energetic and oxidative stress pathways that are disrupted in Friedreich ataxia